Foghorn Therapeutics to Participate in the BMO Oncology Summit

FHTX 10.01.2024

Full Press ReleaseSEC FilingsOur FHTX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025
  • 12.16.2024 - Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities
  • 12.04.2024 - Citi Global Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 12.30.2024 - 4 Statement of changes in beneficial ownership of securities

CAMBRIDGE, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Foghorn®Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in investor meetings at the BMO Oncology Summit being held Tuesday, October 8, 2024, in New York, NY. With an initial focus in oncology, Foghorn’s Gene Traffic Control®platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

About Foghorn TherapeuticsFoghorn®Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control®platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website atwww.foghorntx.comfor more information about the Company, and follow us onXandLinkedIn.

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)khellsvik@foghorntx.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com